NEW YORK (GenomeWeb News) – Exact Sciences has raised $137.7 million in net proceeds from a public offering of 11.5 million shares of common stock.

The firm priced the shares at $12.75 each, which brought in gross proceeds of $146.6 million. Exact Sciences priced the offering of 10 million shares last week. The underwriters on the offering exercised their 1.5 million-share overallotment option in full.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.